Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Cumberland Pharmaceuticals (CPIX) Liabilities from Discontinued Operations (2019 - 2020)

Cumberland Pharmaceuticals' Liabilities from Discontinued Operations history spans 2 years, with the latest figure at 1247011.0 for Q1 2020.

On a quarterly basis, Liabilities from Discontinued Operations changed N/A to 1247011.0 in Q1 2020 year-over-year; TTM through Mar 2020 was 1247011.0, a N/A change, with the full-year FY2019 number at 2151357.0, changed N/A from a year prior.
Liabilities from Discontinued Operations hit 1247011.0 in Q1 2020 for Cumberland Pharmaceuticals, down from 2151357.0 in the prior quarter.
Over the last five years, Liabilities from Discontinued Operations for CPIX hit a ceiling of 2151357.0 in Q4 2019 and a floor of 1247011.0 in Q1 2020.